Literature DB >> 32432681

Nasal ACE2 Levels and COVID-19 in Children.

Ankit B Patel1, Ashish Verma1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32432681     DOI： 10.1001/jama.2020.8946

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  43 in total

1.  Resuscitating Children with COVID-19: What the Pediatric Anesthesiologist Needs to Know.

Authors:  Richard J Ing; Debnath Chatterjee; Mark D Twite
Journal:  J Cardiothorac Vasc Anesth       Date:  2020-06-16       Impact factor: 2.628

2.  Epipharyngeal Abrasive Therapy Down-regulates the Expression of SARS-CoV-2 Entry Factors ACE2 and TMPRSS2.

Authors:  Kensuke Nishi; Shohei Yoshimoto; Soichiro Nishi; Toshiyuki Tsunoda; Jun Ohno; Michinobu Yoshimura; Kenji Hiromatsu; Takafumi Yamano
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

3.  Multisystem Inflammatory Syndrome of a Neonate From a COVID-19-Infected Mother: A Case Report.

Authors:  Abdul Malek; Mukesh Khadga; Md Nurnobi Zahid; Sanjida Mojib; Reena Debnath; Sheela Khan; Mainul Haque; Brian Godman; Salequl Islam
Journal:  Cureus       Date:  2022-03-10

4.  SARS-CoV-2 viral-load distribution reveals that viral loads increase with age: a retrospective cross-sectional cohort study.

Authors:  Sjoerd Euser; Sem Aronson; Irene Manders; Steven van Lelyveld; Bjorn Herpers; Jan Sinnige; Jayant Kalpoe; Claudia van Gemeren; Dominic Snijders; Ruud Jansen; Sophie Schuurmans Stekhoven; Marlies van Houten; Ivar Lede; James Cohen Stuart; Fred Slijkerman Megelink; Erik Kapteijns; Jeroen den Boer; Elisabeth Sanders; Alex Wagemakers; Dennis Souverein
Journal:  Int J Epidemiol       Date:  2021-09-08       Impact factor: 7.196

5.  Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222).

Authors:  Gustavo C Román; Fernando Gracia; Antonio Torres; Alexis Palacios; Karla Gracia; Diógenes Harris
Journal:  Front Immunol       Date:  2021-04-26       Impact factor: 7.561

6.  SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020.

Authors:  Arnaud Fontanet; Laura Tondeur; Rebecca Grant; Sarah Temmam; Yoann Madec; Thomas Bigot; Ludivine Grzelak; Isabelle Cailleau; Camille Besombes; Marie-Noëlle Ungeheuer; Charlotte Renaudat; Blanca Liliana Perlaza; Laurence Arowas; Nathalie Jolly; Sandrine Fernandes Pellerin; Lucie Kuhmel; Isabelle Staropoli; Christèle Huon; Kuang-Yu Chen; Bernadette Crescenzo-Chaigne; Sandie Munier; Pierre Charneau; Caroline Demeret; Timothée Bruel; Marc Eloit; Olivier Schwartz; Bruno Hoen
Journal:  Euro Surveill       Date:  2021-04

7.  Long-Term Persistence of Anti-SARS-CoV-2 Antibodies in a Pediatric Population.

Authors:  Ana Méndez-Echevarría; Talía Sainz; Iker Falces-Romero; Beatriz de Felipe; Lucia Escolano; Sonia Alcolea; Lidia Pertiñez; Olaf Neth; Cristina Calvo
Journal:  Pathogens       Date:  2021-06-04

Review 8.  The Many Faces of Innate Immunity in SARS-CoV-2 Infection.

Authors:  Nicholas Hanan; Ronnie L Doud; In-Woo Park; Harlan P Jones; Stephen O Mathew
Journal:  Vaccines (Basel)       Date:  2021-06-04

9.  High-throughput human primary cell-based airway model for evaluating influenza, coronavirus, or other respiratory viruses in vitro.

Authors:  A L Gard; R J Luu; C R Miller; R Maloney; B P Cain; E E Marr; D M Burns; R Gaibler; T J Mulhern; C A Wong; J Alladina; J R Coppeta; P Liu; J P Wang; H Azizgolshani; R Fennell Fezzie; J L Balestrini; B C Isenberg; B D Medoff; R W Finberg; J T Borenstein
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

Review 10.  COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach.

Authors:  Soha R Abd El Hadi; Esmat E Zien El-Deen; Mostafa M Bahaa; Abdelfattah A Sadakah; Heba A Yassin
Journal:  Drug Des Devel Ther       Date:  2021-07-30       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.